Bronchogen is a short synthetic peptide investigated in preclinical research for its capacity to interact with nuclear chromatin and modulate gene expression pathways in respiratory cell models. Sourcing research-grade Bronchogen from PX1 Research guarantees lot-specific HPLC/MS purity verification, low endotoxin levels, and USA-manufactured quality for rigorous in vitro and ex vivo analytical protocols.
Bronchogen is a short synthetic peptide investigated in preclinical research for its capacity to interact with nuclear chromatin and modulate gene expression pathways in respiratory cell models. Sourcing research-grade Bronchogen from PX1 Research guarantees lot-specific HPLC/MS purity verification, low endotoxin levels, and USA-manufactured quality for rigorous in vitro and ex vivo analytical protocols.
When evaluating a **bronchogen molecular interactions supplier**, research institutions require verified chemical purity, precise sequence fidelity, and comprehensive analytical documentation. Bronchogen is a synthetic bioregulatory peptide comprising four amino acid residues (Ala-Asp-Glu-Leu). Preclinical literature indicates that this short peptide sequence interacts directly with double-stranded DNA and histone proteins, modulating transcriptional activity in broncho-pulmonary cell cultures and tissue explants.
To achieve reproducible data in structural biology and cell culture assays, investigators must utilize peptides free of trifluoroacetic acid (TFA) residual artifacts, heavy metal contaminants, and bacterial endotoxins. PX1 Research supplies high-purity Bronchogen synthesized in GMP-compliant facilities within the United States, backed by independent third-party laboratory verification via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Researchers can explore our full catalog of research compounds across our all peptides hub or review technical documentation in our research library.
Bronchogen (sequence: L-Alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine; H-Ala-Asp-Glu-Leu-OH) possesses a molecular weight of approximately 474.46 g/mol. As a member of the short regulatory peptide family—frequently categorized alongside class-specific Khavinson peptides—its biological activity stems from its primary sequence conformation and side-chain charge distribution under physiological pH conditions.
The presence of acidic side chains (Aspartate and Glutamate) confers a net negative charge at physiological pH, which influences its electrostatic binding behavior with positively charged lysine residues on histone tails and specialized cell surface receptors. In vitro binding assays demonstrate that Bronchogen exhibits selective sequence-dependent binding within the major and minor grooves of genomic DNA, facilitating chromatin decompaction in respiratory epithelial models. Detailed sequence parameters and theoretical mass-to-charge ratios are maintained across all lots available in our wholesale research portal.
Investigations into the molecular interactions of short peptides highlight Bronchogen's capacity to alter gene expression without permanent genomic integration. In vitro assays using human bronchial epithelial cell lines (such as BEAS-2B and NHBE) demonstrate that exposure to Bronchogen correlates with modified transcription rates of genes associated with cellular repair, mucin expression, and antioxidant defense enzymes.
Cell-free binding studies indicate that Bronchogen binds to promoter regions of specific genes, influencing RNA polymerase binding efficiency. Preclinical rodent models further show that the peptide modulates inflammatory cascade signaling pathways—specifically downregulating nuclear factor kappa B (NF-κB) nuclear translocation under induced oxidative stress conditions. This selective transcriptional modulation makes Bronchogen a critical target compound for laboratories studying pulmonary tissue homeostasis, cellular senescence, and epigenetic regulation.
In bioregulatory peptide research, target selectivity depends heavily on amino acid composition and sequence length. Bronchogen is frequently compared against other short oligopeptides to evaluate tissue specificity and differential binding affinities across cellular models.
While Bronchogen focuses on pulmonary tissue models and bronchial epithelial gene regulation, Chonluten (Glu-Asp-Gly) is evaluated for its distinct interactions in lung and tracheal tissue assays. Similarly, broader repair-focused compounds such as BPC-157 operate via growth factor receptor crosstalk and angiogenic pathways, whereas short peptides like Bronchogen modulate chromatin accessibility directly. Investigating these distinct mechanisms provides baseline data for multi-peptide screening assays in tissue engineering and cellular senescence protocols.
For quantitative in vitro assays, raw peptide material must satisfy strict quality thresholds. Impurities resulting from incomplete solid-phase peptide synthesis (SPPS)—such as deletion sequences or unblocked side-chain derivatives—can interfere with binding constant measurements and receptor interaction studies.
PX1 Research ensures that every batch of Bronchogen undergoes rigorous analytical testing at an ISO 17025 accredited testing facility. Quality assurance criteria include:
• Purity Determination: Reverse-Phase HPLC (RP-HPLC) analysis confirming peptide purity exceeding 98.0% peak area integration. • Mass Verification: Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF confirming correct monoisotopic mass (474.46 Da ± 0.5 Da). • Counterion Management: Controlled desalting processes to minimize TFA concentration, preventing false-positive cytotoxicity in sensitive cell cultures. • Endotoxin Testing: Limulus Amebocyte Lysate (LAL) assay verification guaranteeing endotoxin levels strictly below 0.01 EU/mg, preventing unspecific toll-like receptor activation in vitro.
Research-grade Bronchogen is supplied as a lyophilized (freeze-dried) powder to maximize chemical stability during transport and storage. Proper handling protocols must be observed to maintain molecular integrity prior to experimental assays:
1. Reconstitution Medium: Lyophilized Bronchogen should be reconstituted using sterile, cell-culture grade Water for Injection (WFI) or sterile Phosphate-Buffered Saline (PBS, pH 7.4). For assays sensitive to ionic strength, low-salt buffer systems may be utilized. 2. Solubilization: Gentle swirl agitation is recommended. High-shear vortexing or sonicating should be minimized to avoid peptide aggregation or mechanical degradation. 3. Storage Parameters: Lyophilized vials should be stored at -20°C or -80°C upon receipt, protected from moisture and light. Following reconstitution, working aliquots should be frozen at -80°C to avoid repeated freeze-thaw cycles, which induce peptide breakdown.
For additional handling guidelines and laboratory storage specifications, consult the technical documentation within our research library.
Selecting a reliable supplier for peptide research requires scrutinizing production methods, transparency, and lot traceability. Suppliers providing unverified or off-shore synthesized compounds often lack lot-specific Certificates of Analysis (COAs), presenting risks of chemical contamination or variable sequence accuracy.
PX1 Research distinguishes itself by manufacturing peptides domestically within the USA in GMP-compliant facilities. Every shipment includes downloadable, lot-specific COAs featuring raw chromatograms and mass spectra data. Operating out of centralized dispatch hubs in California and Arizona, PX1 Research provides same-day shipping (Monday–Friday) to support uninterrupted research schedules for academic, pharmaceutical, and institutional laboratories.
What is the primary sequence of Bronchogen?
Bronchogen is a synthetic tetrapeptide with the amino acid sequence L-Alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (H-Ala-Asp-Glu-Leu-OH).
How does Bronchogen interact with DNA in research models?
Preclinical in vitro studies show that Bronchogen binds electrostatically and sequence-specifically to double-stranded DNA grooves, modulating chromatin packing and influencing gene transcription in epithelial cell lines.
What purity level is required for Bronchogen in laboratory assays?
Analytical molecular interaction assays typically require a peptide purity of >98% as measured by RP-HPLC, with low endotoxin levels (<0.01 EU/mg) to prevent non-specific cellular responses.
What solvent should be used to reconstitute Bronchogen for in vitro work?
Reconstitution is recommended using sterile cell-culture grade water (WFI) or sterile Phosphate-Buffered Saline (PBS, pH 7.4). Aliquots should be stored at -80°C to prevent degradation.
How does PX1 Research verify Bronchogen purity?
PX1 Research subjects every batch of Bronchogen to third-party ISO 17025 laboratory testing, utilizing RP-HPLC for purity and ESI-MS for exact mass identity confirmation.
Is Bronchogen supplied for human administration or clinical use?
No. Bronchogen provided by PX1 Research is strictly designated for laboratory research use only (in vitro and preclinical models) and is not intended for human or veterinary use.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research peptides are manufactured in US-based GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona with same-day dispatch on business days.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.